Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma

Inclusion Criteria: * Histologically or cytologically confirmed ovarian adenocarcinoma * Patients had to have received a front-line, platinum- based chemotherapy regimen * Patients who progressed or whose best response to their most recent platinum-based therapy was less than a partial response will be classified as having platinum-refractory/resistant ovarian cancer. This category also will include patients with disease progression within six months of completing the most recent platinum-based chemotherapy * Patients had to have at least one bidimensionally measurable and/or evaluable (unidimensionally measurable) target lesion in a non-irradiated area, or increased Ca 125 * A \>= 4 weeks interval between their last chemotherapy regimen and the start of study treatment * Age \> 18 years old * Performance status (WHO) 0-2 * Life expectancy of at least three months * Adequate bone marrow function (absolute neutrophil count \> 1000/mm\^3, platelet count \> 100000/mm\^3, hemoglobin \> 9 gr/mm\^3) * Adequate liver (bilirubin \< 1.5 times upper limit of normal and SGOT/SGPT \< 2 times upper limit of normal) and renal function (creatinine \< 2 mg/dl) * Informed consent Exclusion Criteria: * Pregnant or nursing * Psychiatric illness or social situation that would preclude study compliance * Other concurrent uncontrolled illness * Other invasive malignancy within the past 5 years except nonmelanoma skin cancer